<SEC-DOCUMENT>0001193125-21-062094.txt : 20210301
<SEC-HEADER>0001193125-21-062094.hdr.sgml : 20210301
<ACCEPTANCE-DATETIME>20210301060615
ACCESSION NUMBER:		0001193125-21-062094
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20210301
FILED AS OF DATE:		20210301
DATE AS OF CHANGE:		20210301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		21693561

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 5
		STREET 2:		20 GEORGE STREET
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 5
		STREET 2:		20 GEORGE STREET
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d143798d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of March, 2021 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia
Therapeutics Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9745;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; &#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if
the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule
101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by
check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which
the registrant is incorporated, domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on
EDGAR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;&#9745; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
&#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Kazia Therapeutics Limited</B> <B></B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Kate Hill </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kate Hill </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 1&nbsp;March 2021 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g143798g45f49.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX RELEASE </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1&nbsp;March
2021 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KAZIA LICENSES CANTRIXIL, A CLINICAL-STAGE, FIRST-IN-CLASS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OVARIAN CANCER DRUG CANDIDATE, TO OASMIA PHARMACETICAL AB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sydney,</B><B> 1&nbsp;March 2021</B> &#150; Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is
pleased to announce that it has entered into an exclusive worldwide license agreement with Oasmia Pharmaceutical AB (STO: OASM), an innovation-focused specialty pharmaceutical company, for Cantrixil <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(TRX-E-002-1),</FONT></FONT></FONT> a clinical-stage, first-in-class drug candidate under development for the treatment of ovarian cancer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Points </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oasmia will assume worldwide exclusive rights to develop and commercialise Cantrixil for all indications, with an
initial focus on ovarian cancer </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Under the terms of the agreement, Oasmia will make an upfront payment of US$ 4 million to Kazia, with contingent
milestone payments of up to US$ 42 million, and double-digit royalties on commercial sales </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oasmia is an innovative specialty pharmaceutical company, based in Stockholm, Sweden. Its lead product, Apealea<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (paclitaxel micellar), is approved in Europe for adult patients with first relapse of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer, and is in
late-stage clinical development in the US </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oasmia expects to commence a Phase II study of Cantrixil in ovarian cancer in 2022 </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia CEO, Dr James Garner, commented, &#147;Oasmia possesses deep expertise in the field of ovarian cancer, and also brings to Cantrixil a highly commercial
focus, world-class formulation capabilities, and an extensive network of clinician relationships in Europe and the US. This transaction follows the release of very encouraging top-line data from the phase&nbsp;I study of Cantrixil late last year.
Our strategy has been to seek a partner for Cantrixil&#146;s further development, and we are delighted to now pass the baton to the Oasmia team.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr
Fran&#231;ois Martelet, CEO of Oasmia, added, &#147;Cantrixil is an exciting addition to Oasmia&#146;s oncology pipeline and builds on our development expertise in ovarian cancer. Expanding Oasmia&#146;s portfolio of therapies and technologies is a
key pillar of our transformation strategy. Acquiring rights to Cantrixil, which has established clinical proof of concept, is a major step forward in executing this strategy, and we will continue to leverage our development and partnering expertise
to build our oncology pipeline.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cantrixil (TRX-E-002-1) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantrixil is a proprietary formulation of the potent and selective third-generation benzopyran, TRX-E-002-1. It targets the entire spectrum of cancer cells,
including chemotherapy-resistant tumour-initiating cells (&#145;cancer stem cells&#146;) that are thought to be responsible for disease relapse. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
December 2020, Kazia announced top-line results of a Phase I open-label study (NCT02903771) conducted at sites in the US and Australia, covering both monotherapy and combination therapy in patients with persistent or recurrent ovarian, fallopian
tube or primary peritoneal cancer. The Phase I study met its primary endpoints, and full data are expected to be published in a peer-reviewed scientific journal during CY2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantrixil was granted orphan designation for ovarian cancer by the US FDA in April 2015. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For Further Information: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gabriella Hold </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IR Department </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>gabriella.hold@irdepartment.com.au</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel: +61 411 364 382 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes
two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program is
paxalisib (formerly GDC-0084), a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late
2016, paxalisib entered GBM AGILE, a pivotal study in glioblastoma, in October 2020. Seven additional studies are active in various forms of brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018,
and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TRX-E-002-1 (Cantrixil) is a third generation benzopyran molecule with activity against cancer stem cells and is being developed to treat ovarian cancer.
TRX-E-002-1 has completed a phase I clinical trial in Australia and the United States. Cantrixil was granted orphan designation for ovarian cancer by the US FDA in April 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit <U>www.kaziatherapeutics.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Oasmia Pharmaceutical AB </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oasmia is a specialty
pharma company dedicated to improving the lives of patients by enhancing the intravenous delivery of established and novel drugs in significant diseases, including cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Product development is primarily based on the Company&#146;s proprietary drug delivery technology platform
XR-17<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> which can be applied to medicines used in many therapeutic areas, to develop water soluble formulations of drugs that currently require chemical solubilizers for dissolution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The first product approved using this technology is Apealea<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (paclitaxel micellar). Apealea has
received market authorization in the European Union and several other territories for the treatment of first relapse in platinum-sensitive ovarian cancer, in combination with carboplatin. The Company is making Apealea accessible to patients through
its partnership with Elevar Therapeutics, together with its existing commercial operations in the Nordic region. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oasmia&#146;s shares are traded on the
Nasdaq Stockholm stock exchange (ticker: OASM). To find out more about Oasmia please visit <U>www.oasmia.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document was authorized for
release to the ASX by James Garner, Chief Executive Officer, Managing Director. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g143798g45f49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g143798g45f49.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M# P,# P,# P,#/_  !$( (X#- ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
M         0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T! @, !!$%
M$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U
M-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*
MDI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:
MX>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!         0(#
M! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&$D%1!V%Q
M$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%
M1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8
MF9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?H
MZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\)P*3<*24XC;Z5^:_Q<_X.2O
M_P (OC%XR\&W'PQ\:7UUX+\0:CX>GNH;VT2*YELKJ6V>1 S;@K-$6 /.".^:
MUI49U':"N9U*T*:O-V/TIW"C<*_+?_B*,\!?]$G\=_\ @PLO_BZ/^(HOP#_T
M2GQY_P"#"Q_^+K7ZCB/Y&<_UZA_.C]2-PHW"ORW_ .(HOP#_ -$I\>?^!]C_
M /%T?\11G@+_ *)/X[_\&%E_\71]1Q'\C#Z]0_G1^I&X4;A7Y;_\11G@(_\
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M1G@'_HE'CS_P86/_ ,71]1Q'\C#Z]0_G7XGZD;A1N%?EO_Q%%^ ?^B4^//\
MP/L?_BZ/^(HSP"/^:4^//_!A8_\ Q='U'$?R,/KU#^='ZD;A1N%?EO\ \11G
M@+_HD_CO_P &%E_\71_Q%%^ ?^B4^//_  86/_Q='U'$?R,/KU#^=?B?J1N%
M&X5^6_\ Q%%^ ?\ HE/CS_P86/\ \71_Q%&> O\ HD_CO_P867_Q='U'$?R,
M/KU#^=?B?J1N%&X5^6__ !%&> 3_ ,TH\>?^#"Q_^+H_XBB_ /\ T2GQY_X'
MV/\ \71]1Q'\C']>H?SH_4C<*-PK\M_^(HSP$/\ FE'CS_P86/\ \71_Q%&>
M O\ HD_CO_P867_Q='U'$?R,7UZA_.OQ/U(W"C<*_+?_ (BB_ /_ $2GQY_X
M'V/_ ,71_P 11?@'_HE/CS_P86/_ ,73^HXC^1C^O4/YU^)^I&X4;A7Y;_\
M$49X"_Z)/X[_ /!A9?\ Q='_ !%&> 3_ ,TH\>?^#"Q_^+I?4<1_(Q?7J'\Z
M_$_4C<*-PK\M_P#B*+\ _P#1*?'G_@?8_P#Q='_$49X"_P"B3^.__!A9?_%T
M?4<1_(P^O4/YU^)^I&X4;A7Y;_\ $49X"_Z)/X[_ /!A9?\ Q='_ !%%^ ?^
MB4^//_ ^Q_\ BZ/J.(_D8?7J'\Z_$_4C<*-PK\M_^(HOP#_T2GQY_P"#"Q_^
M+H_XBC/ 7_1)_'?_ (,++_XNCZCB/Y&'UZA_.OQ/U(W"C<*_+?\ XBB_ /\
MT2GQY_X,+'_XNC_B*+\ _P#1*?'G_@?8_P#Q='U'$?R,/KU#^='ZD;A1N%?E
MO_Q%&> O^B3^._\ P867_P 71_Q%&> O^B4>._\ P86/_P 71]1Q'\C#Z]0_
MG7XGZD;A1N%?EO\ \11?@'_HE/CS_P #['_XNC_B*,\!#_FE'CS_ ,&%C_\
M%T?4<1_(P^O4/YT?J1N%&X5^6_\ Q%&> O\ HD_CO_P867_Q='_$47X!_P"B
M4^//_!A8_P#Q='U'$?R,/KU#^=?B?J1N%&X5^6__ !%%^ ?^B4^//_ ^Q_\
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MC/ 7_1*/'G_@PL?_ (NCZCB/Y&'UZA_.OQ/U(W"C<*_+?_B*+\ _]$I\>?\
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MP%_T2?QW_P"#"R_^+H^HXC^1B^O4/YU^)^I&X4;A7Y;_ /$47X!_Z)3X\_\
M ^Q_^+H_XBB_ /\ T2GQY_X,+'_XNG]1Q'\C']>H?SK\3]2-PHW"ORW_ .(H
MSP%_T2?QW_X,++_XNC_B*+\ _P#1*?'G_@PL?_BZ7U'$?R,7UZA_.OQ/U(W"
MC<*_+?\ XBB_ /\ T2GQY_X'V/\ \71_Q%&> O\ HE'CO_P86/\ \71]1Q'\
MC#Z]0_G7XGZD;A1N%?EO_P 11G@+_HE'CO\ \&%C_P#%T?\ $47X!_Z)3X\_
M\#['_P"+H^HXC^1A]>H?SH_4C<*-PK\M_P#B*,\ C_FE'CS_ ,&%C_\ %T?\
M11G@+_HD_CO_ ,&%E_\ %T?4<1_(P^O4/YU^)^I&X4;A7Y;_ /$47X!_Z)3X
M\_\ !A8__%T?\11?@'_HE/CS_P #['_XNCZCB/Y&/Z]0_G1^I&X4;A7Y;_\
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M-'_?- !C_=HQ_NT?]\T?]\T &/\ =HQ_NT?]\T?]\T &/]VC'^[1_P!\T?\
M?- !C_=HQ_NT?]\T?]\T &/]VC'^[1_WS1_WS0 8_P!VC'^[1_WS1_WS0 8_
MW:,?[M'_ 'S1_P!\T &/]VC'^[1_WS1_WS0 8_W:,?[M'_?-'_?- !C_ ':,
M?[M'_?-'_?- !C_=HQ_NT?\ ?-'_ 'S0 8_W:,?[M'_?-'_?- !C_=HQ_NT?
M]\T?]\T &/\ =HQ_NT?]\T?]\T &/]VC'^[1_P!\T?\ ?- !C_=HQ_NT?]\T
M?]\T &/]VC'^[1_WS1_WS0 8_P!VC'^[1_WS1_WS0 8_W:,?[M'_ 'S1_P!\
MT &/]VC'^[1_WS1_WS0 8_W:,?[M'_?-'_?- !C_ ':,?[M'_?-'_?- !C_=
MHQ_NT?\ ?-'_ 'S0 8_W:,?[M'_?-'_?- !C_=HQ_NT?]\T?]\T &/\ =HQ_
MNT?]\T?]\T &/]VC'^[1_P!\T?\ ?- !C_=HQ_NT?]\T?]\T &/]VC'^[1_W
MS1_WS0 8_P!VC'^[1_WS1_WS0 ZV'^D1_=^]VK^E3_@CU_RBN_9[_P"Q!TC_
M -)8Z_FKM_\ CXC^[]ZOZ5/^"/7_ "BN_9[_ .Q!TC_TECKQLZ_AQ]?T1ZN3
M_'+T_5GTA1117SA[XV3_ %;?2OY8?VSSC]M[X[?=_P"2F>*.O_89O*_J>D_U
M;?2OY8?VSSC]M[X[<_\ -3/%'_IYO*]C)?XK]/U/'SC^''U/.=W^[1N_W:-W
M^T/RHW?[0_*OI#PPW?[M&[_=HW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M
M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=
MHW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T
M/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\
M=HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0
M_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]
MVC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#
M\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W
M:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M
M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=
MHW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T
M/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\
M=HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0
M_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]
MVC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#
M\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W
M:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M
M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=
MHW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T
M/RH -W^[1N_W:-W^T/RHW?[0_*@!UL?](C^[][M7]*G_  1Z_P"45W[/?_8@
MZ1_Z2QU_-7;G-Q'R/O5_2I_P1Z_Y17?L]_\ 8@Z1_P"DL=>-G7\./K^B/6RC
MXY>GZL^D****^</>&R?ZMOI7\L/[9YQ^V]\=N?\ FIGBCM_U&;NOZGI/]6WT
MK^6']L\X_;>^.W/_ #4SQ1V_ZC-Y7LY+_%?I^IX^<?PX^IYSN_VOTHW?[7Z4
M;O\ :_2C=_M?I7T9X8;O]K]*-W^U^E&[_:_2C=_M?I0 ;O\ :_2C=_M?I06]
M_P!*]NT[]A_4-0_X)XZA^T"OB73_ "K#4VB_X1EK<&ZETX:A_9C:CYBR;MBW
M@*&(1Y*JS;^1B)5(QMS/?0J,7+X?4\1W?[7Z4;O]K]*]R^*?[%EI\&OV:M$\
M;ZM\1]"7Q5KWA#2O'FG^$'LGBN-2TF]E,:+973LL5W?1 ;Y;95QM/$FTAJT_
MVC/^">M_\ /!"^(H?%2^)M)\4:WI.C_#633]+8R_$>*^LH[QKNWA\TR1Q0K<
M16^%$IDG94#*<9S6*I-V3-/J]1=#YZW?[7Z4;N>M>H?LY_LJ:]^TSI'Q(_X1
M\S2>(OA_9:;-;:.MH9)-9NK[41816V[<OV?#X=G<-M (*CDKW?PT_8F\#_$3
M]KC5/@Y;_&2:;7H=;A\/:+=Z=X(N=2A\077E.U\%\NX BAM&20&9CB1$,J;5
MXISQ$(WOTW%&A.232WV/G3=S][]*-W^U^E>__L^_L&_\-*ZG\7E\.^.-/DT_
MX=S7-GX9NDTYYQ\0[I(=1N;>WM,2 1F6TL#,&;?@2J<$Y)\;^&G@L?$W1/&5
MY#??91X2\+-XF4&$O]L OK"U\GJ-G_'[OW8/,6W&&R"->#Z[?KL'L)JUUO\
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M?I1N_P!K]*-W^U^E&[_:_2@ W?[7Z4;O]K]*-W^U^E&[_:_2@ W?[7Z4;O\
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M1#ACDAB-PKTJ.7WA"M5DHP<K/NO.Q\WBL_:KU<%A*;G5C#FC?2+?:YX+XA\
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M"VT'@MC )&2,C/0?\,]_$3_HG_CS_P )V]_^-5,IQ3LV-1;V.1W?[7Z4;O\
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M_+#^V?\ \GO?';[W_)3/%'_IYO*]C)?XK]/U/'SC^''U/.<^[?E1GW;\J/\
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MY49]V_*C_OJC_OJ@ S[M^5&?=ORH_P"^J/\ OJ@ S[M^5&?=ORH_[ZH_[ZH
M,^[?E1GW;\J/^^J/^^J #/NWY49]V_*C_OJC_OJ@ S[M^5&?=ORH_P"^J/\
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M;M2\;LNK^(U1OFM]*A?]W$3U7[1<*J\9W1PSCCJ/QI<_,WS-U)SLVY_#H*]
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M^*O!G@%=8C\3>)=0\'1>'[W7KFXFU"YC@L8M/749;=HFM-0FNKBXE2"'9&\
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MV?UHQ_LK1C_96@ Q_L_K1C_9_6C'^RM&/]E: #'^S^M&/]G]:,?[*T8_V5H
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MXJ_I4_X(]?\ **[]GO\ [$'2/_26.OYJ[8?Z1'POWNU?TJ?\$>O^45W[/?\
MV(.D?^DL=>-G7\./K^B/6RCXY>GZL^D****^</>&SAC"VW[V.*_'/X]_\&W?
MQ/\ BU^T)\1/&%C\0O =K8^,_%FK^(;:WN+>[::WBO+Z>Y2-RJXW*LH4XR,@
M\D5^QQ&10%Q6]#$5*+YJ;,:V'A55IH_$?_B%_P#BS_T4GX<_^ M[_P#$T?\
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M]_P#^S*';\6?B/\ \0P'Q8_Z*5\.?_ :]_\ B:/^(8#XL?\ 12OAS_X#7O\
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M]_P#^S:';\6?B.?^#8#XL9_Y*5\.?_ :]_\ B:/^(8#XL?\ 12OAS_X#7O\
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M/?\  /[-H=OQ9^(Y_P"#7_XLX_Y*3\.?_ 6]_P#B:/\ B& ^+'_12OAS_P"
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8@8KGKXNK6_B,Z*.%ITM8(****YSH/__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
